+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are studying the effects of the drug ZT-01 on nighttime low blood sugar hypoglycemia in adults with type 1 diabetes who experience low blood sugars at night. The study aims to find out if ZT-01 can reduce the number of nighttime hypoglycemia episodes and how it affects blood sugar levels. The safety of ZT-01 will also be evaluated during this phase 2a trial sponsored by Zucara Therapeutics Inc. Participants will receive both placebo and ZT-01 at one of three dose levels 7 mg, 15 mg, or 22 mg, injected under the skin daily for 28 days each. The study uses a randomized, double-blind, crossover design, so participants will receive ZT-01 during one period and placebo during another, without knowing which they are receiving. They will wear a continuous glucose monitor CGM provided by the study during treatment periods and continue their usual blood sugar monitoring and insulin use. During the approximately 16-week study, participants will have up to 6 visits and 2 phone calls. They will provide blood and urine samples to assess eligibility and effects of treatment, have blood pressure and temperature checked at visits, and receive ECGs at 4 visits to monitor heart activity. Some participants may join a sub-study requiring overnight stays for blood level tests of ZT-01 and glucagon. Participants will complete daily diaries and upload CGM data to a study phone for ongoing monitoring. The main outcome measured is the number of nighttime hypoglycemia episodes during each 28-day treatment period.

Age: 18Years - 75YearsAll GendersPhase 2
46 locations
S

Actively Recruiting

This research aims to develop and validate a single-gene Non-Invasive Prenatal Test sgNIPT to detect serious health conditions like cystic fibrosis, spinal muscular atrophy, sickle cell disease, and thalassemias in unborn babies. It focuses on pregnant people with higher risk pregnancies due to carrier status or affected conditions, including cases without reproductive partner screening. The study will gather blood samples and medical information from pregnant participants and, when applicable, their partners and newborns. Participants will undergo the investigational sgNIPT, which is designed for pregnant people whose fetus is at increased risk for a single-gene disorder. This includes situations where there is no partner screening, positive partner screening but no prenatal diagnostic testing, or ultrasound findings suggesting a single-gene disorder regardless of carrier status. The study will collect newborn cheek swabs and health data within six months after delivery as part of the research. During the study, participants will provide blood samples after nine weeks of pregnancy, and researchers will collect medical and genetic information from participants and their partners. Newborn health information and cheek swabs will be collected post-delivery to assess the tests performance. The primary outcome is the accuracy of the sgNIPT in detecting four main autosomal recessive disorders approximately two years after study launch, followed by evaluation of other single gene disorders about six months later. Participation involves consenting to these procedures and ongoing information sharing throughout the study period.

Age: 18Years +All Genders
18 locations
P

Actively Recruiting

Researchers are evaluating whether stereotactic body radiotherapy SBRT given to all sites of disease in patients with 1 to 5 metastatic cancer lesions can delay the progression of their condition. This study focuses on patients with metastatic breast cancer or non-small cell lung cancer, aiming to see if adding SBRT to standard treatments can extend the time before the disease worsens. Participants are assigned to one of two groups. One group receives the standard care treatment determined by their oncologist, which may include chemotherapy, targeted therapy, immunotherapy, or hormonal therapy. The other group receives SBRT targeted to all visible metastatic sites, with radiation doses tailored by the radiation oncologist, alongside standard systemic therapies. SBRT is delivered concurrently to all metastatic sites, and after completion, standard care continues. Radiation doses vary depending on the location of metastases, with specific dosing recommendations for lung and bone metastases. Throughout the study, participants will be monitored for how long their cancer remains stable without worsening, with follow-up lasting up to two years to assess progression-free survival and overall survival. Researchers will perform imaging studies and clinical assessments to measure disease status. Patients may continue systemic therapy during SBRT as advised by their doctors. Safety and effectiveness of the combined treatments will be carefully tracked during the study period.

Age: 18Years +All GendersPhase 2
12 locations
I

Actively Recruiting

Researchers are studying females aged 45 and older who have abnormal uterine bleeding AUB or postmenopausal bleeding PMB to develop a non-invasive test that can help rule out gynecological cancer. This observational study focuses on distinguishing between benign and malignant causes of bleeding in these women. Participants will provide samples that are collected to compare those with benign causes to those with malignant causes of AUB or PMB. The study groups include females with benign conditions and those with malignant conditions, aiming to identify characteristics that can improve diagnostic accuracy. During the study, participants will follow scheduled visits and procedures to provide samples and information. Researchers will monitor the sensitivity and specificity of the new diagnostic test over 12 months. Participants are expected to remain available and reachable throughout the study duration, which lasts until November 2031.

Age: 45Years - 100YearsFEMALE
16 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
P

Actively Recruiting

Researchers are investigating how aerobic exercise might help prevent the return of cancer by lowering circulating tumor DNA ctDNA levels in the blood. This study focuses on patients who have previously been treated for breast, prostate, or colorectal cancer and are considered at high risk for relapse. The research aims to find the highest practical and safe level of exercise that positively affects the body and may reduce ctDNA levels to help prevent cancer from coming back. The study includes two phases. In phase 1a, up to 50 post-treatment patients with colorectal or breast cancer will be assigned to one of five increasing exercise doses, ranging from 90 to 375 minutes per week, delivered as individualized walking sessions 3 to 6 times weekly. The exercise dose is adjusted non-linearly with rest and recovery periods over up to 18 months or until disease progression or withdrawal. Phase 1b involves an independent group of 30 patients testing the recommended phase 2 dose RP2D identified in phase 1a to further assess its feasibility, safety, and biological activity. Participants will complete exercise therapy while researchers monitor the effects on ctDNA levels and overall safety. Exercise participation is tracked using remote activity and heart rate monitoring over 7-day periods before study entry. The primary outcome is to identify the recommended phase 2 dose of exercise after 24 weeks. The study also evaluates the exercise therapys feasibility and biological effects in the follow-up phase. Participants remain in the study until disease progression or withdrawal, with ongoing monitoring throughout the treatment period.

Age: 18Years +All GendersPhase Not Applicable
9 locations